Fundraising Fox
Telo Therapeutics, Inc.
San Francisco, US · Founded 2015 · Delaware corporation · 2 employees on LinkedIn · 1 known investors
Find your way into Telo Therapeutics, Inc.
Sign up to see every warm intro you have to Telo Therapeutics, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Telo Therapeutics, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Telo Therapeutics is a biotechnology company developing orally bioavailable next-generation small-molecule inhibitors of nuclear transport as cancer treatments. Its lead program targets multiple myeloma and other cancers, and the company is raising a Series A to advance toward IND and a Phase 1 trial.
Founders & leadership
Telo Therapeutics, Inc. was founded in 2015 by Rob Bell and Robert Bell Ph.D..
RB
Rob BellCo-Founder and CEORob Bell holds a Bachelor's degree from Boston College and a PhD in cancer genetics and molecular biology from UCSF, where he conducted graduate research under Dr. Joseph Costello. He is the founder and CEO of Telo Therapeutics, a San Francisco-based biotechnology company developing small-molecule inhibitors of nuclear transport for cancer treatment.
RB
Robert Bell Ph.D.CEO & Co-Founder
JC
Joseph CostelloNamed on SEC filing
MD
Board
RG
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.7M disclosed across 1 round · 2021
▶$4.7MraisedJun 2022 · 12 investors · BiotechnologyRule 506(b)
▶$4.7MraisedJun 2022 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert G. BlazejDirector
- Robert BellExecutive Officer, Director
- Joseph CostelloDirector
- Michael D. TaylorDirector
- Offering amount
- $10.2M
- Amount sold
- $4.7M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
RelayRelay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.
Companies working in the same space as Telo Therapeutics, Inc..
In the news
Frequently asked questions
- What does Telo Therapeutics, Inc. do?
- Telo Therapeutics is a biotechnology company developing orally bioavailable next-generation small-molecule inhibitors of nuclear transport as cancer treatments. Its lead program targets multiple myeloma and other cancers, and the company is raising a Series A to advance toward IND and a Phase 1 trial.
- Who founded Telo Therapeutics, Inc.?
- Telo Therapeutics, Inc. was founded by Rob Bell, Robert Bell Ph.D. in 2015.
- Who are Telo Therapeutics, Inc.'s investors?
- Telo Therapeutics, Inc.'s investors include Mission Biocapital.
- How much funding has Telo Therapeutics, Inc. raised?
- Telo Therapeutics, Inc. has disclosed $4.7M raised across 1 round.
- Where is Telo Therapeutics, Inc. headquartered?
- Telo Therapeutics, Inc. is headquartered in San Francisco, US.